Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study

Abstract

Introduction

Shigellosis, is a leading cause of moderate-to-severe diarrhoea and related mortality in young children in low and middle income countries (LMICs). Knowledge on naturally acquired immunity can support the development of Shigella candidate vaccines mostly needed in LMICs. We aimed to quantify Shigella-specific antibodies of maternal origin and those naturally acquired in Zambian infants.

Methods

Plasma samples collected from infants at age 6, 14 and 52-weeks were tested for Shigella (S. sonnei and S. flexneri 2a) lipopolysaccharide (LPS) antigen specific immunoglobulin G (IgG) and A (IgA) by enzyme-linked immunosorbent assay.

Results

At 6 weeks infant age, the IgG geometric mean titres (GMT) against S. sonnei (N = 159) and S. flexneri 2a (N = 135) LPS were 311 (95% CI 259–372) and 446 (95% CI 343–580) respectively. By 14 weeks, a decline in IgG GMT was observed for both S. sonnei to 104 (95% CI 88–124), and S. flexneri 2a to 183 (95% CI 147–230). Both S. sonnei and S. flexneri 2a specific IgG GMT continued to decrease by 52 weeks infant age when compared to 6 weeks. In 27% and 8% of infants a significant rise in titre (4 fold and greater) against S. flexneri 2a and S. sonnei LPS, respectively, was detected between the ages of 14 and 52 weeks.

IgA levels against both species LPS were very low at 6 and 14 weeks and raised significantly against S. flexneri 2a and S. sonnei LPS in 29% and 10% of the infants, respectively.

Conclusion

In our setting, transplacental IgG anti-Shigella LPS is present at high levels in early infancy, and begins to decrease by age 14 weeks. Our results are consistent with early exposure to Shigella and indicate naturally acquired IgG and IgA antibodies to S. flexneri 2a and S. sonnei LPS in part of infants between 14 and 52 weeks of age. These results suggest that a potential timing of vaccination would be after 14 and before 52 weeks of age to ensure early infant protection against shigellosis.

Introduction

Generally, by the age of five, infants suffer repeated bouts of diarrhoea [1] and account for approximately 688 million illnesses and 499,000 deaths [2, 3]. Majority of these deaths (90%) occur in South Asia and sub-Saharan Africa [4]. The Global Enteric Multicentre Study (GEMS study) on burden and aetiology of moderate-to-severe (MSD) diarrhoeal disease in children aged <5 years found that Shigella was among the four most common pathogens across sites and age strata in Africa and Asia [5]. In Zambia, Shigella is reported to be the second leading attributable cause of MSD in children <5 years old with an estimated prevalence of 35% [6]. There are four Shigella serogroups, Shigella flexneri (S. flexneri), Shigella sonnei (S. sonnei), Shigella dysenteriae (S. dysenteriae) and Shigella boydii (S. boydii) with >40 identified serotypes across these groups. Previous reports show that in low- and middle-income countries (LMICs), S. flexneri 2a accounts for most cases of shigellosis in children <5 years old [5] while in high income countries S. sonnei is said to be responsible for the vast majority of cases [7]. However, there has been a notable shift towards increasing rates of S. sonnei infections being reported in LMICs now than before [8].

The burden of disease and the emerging global increase in antimicrobial resistance of Shigella [9, 10] clearly demand for enhanced interventions to avert the reported cases and deaths. The primary prevention of Shigellosis is based on universal access to safe water, improved sanitation and personal and food hygiene [11]. Development of an efficacious and affordable vaccine would complement and accelerate disease reduction, particularly in LMICs where primary preventive methods are practically unattainable in the short to medium term. Unfortunately, there is a dearth of both epidemiological and immunological information on Shigella infection and disease from endemic settings, a gap which needs to be filled to support important vaccine development and deployment work.

Shigella infection confers around 70% serotype specific immunity for a limited period of time [12, 13]. Data from both high and middle income countries (HMICs) [14] and LMICs [15] showed that the incidence of culture proven Shigellosis is lowest in the first year of life in children <5 years old and it is postulated that this is due to protective levels of Shigella specific serum immunoglobulin G (IgG) of maternal origin [16]. Presence of S. sonnei and S. flexneri 2a anti-lipopolysaccharide (LPS) IgG in cord blood and it’s strong correlation with levels in mothers colostrum immediately after delivery has been reported [17]. In Vietnamese infants, the median half-life of maternal anti-S. sonnei LPS IgG was 43 days after birth [18]. Following a finding that Shigella specific anti-LPS IgG antibodies were strongly associated with protection in sero-epidemiological studies carried out in Israel [19, 20], injectable Shigella conjugate vaccines have been developed [21]. The S. sonnei conjugate vaccines showed 74% protective efficacy in young adults and 71% protection in children aged 3–4 years in efficacy trials in Israel, but failed to protect children less than 3 months old [22]. The studies also showed that serum IgG anti-LPS levels correlated with protection.

Recently, second generation and new formulations of monovalent subunit parenteral Shigella vaccine candidates including synthetic carbohydrate-based conjugates [23], bio conjugates [24] as well as the Generalized Modules for Membrane Antigen (GMMA) particles have been developed [25]. The S. sonnei vaccine (1790GAHB) also showed good immunogenicity in phase 2a study with significant increases in geometric mean concentration between baseline and 29 days after a single dose [26]. Also some preliminary protective efficacy in controlled human infection challenge studies in adults in the US where also observed with Flexyn2a, a candidate bioconjugate vaccine against S. flexneri 2a [27]. While additional challenge studies are presently underway, the next important stage ought to be the evaluation of the immunogenicity and safety of these candidates in paediatric age descending studies in LMICs.

Therefore, we sought to quantify serum antibodies specific to S. flexneri 2a and S. sonnei LPS in Zambian infants and assess duration of specific IgG of maternal origin. We aimed to also propose a potential window for future infant immunisation with a Shigella injectable vaccine in relation to the timing of early natural exposure to Shigella as documented by IgG and IgA seroconversion to Shigella LPS.

Methods

Study design and participants

We used existing data and stored biological samples collected from a longitudinal cohort of mother-infant pairs previously enrolled in an observational rotavirus vaccine study at Kamwala Clinic in Lusaka Zambia. Kamwala Clinic is a peri-urban Primary Healthcare Facility providing basic outpatient and maternal child health services to a low-income catchment population.

Briefly, participants were enrolled during their routine immunisation clinic visits. The study staff approached the mother-infant pairs at the initial visit with study material. Interested individuals were provided with detailed study information and consented accordingly. A comprehension test was administered and only those meeting the minimum understanding provided individual written consent. Illiterate mothers were provided information through an impartial witness who provided a signed confirmation together with thumbprint of the participant as confirmed written consent. Principally, the pair was eligible if: i) there was willingness by the mother to participate including provision of a signed informed consent; ii) the infant was eligible for rotavirus vaccine immunisation per national policy (male or female infant, aged 6–12 weeks old); iii) the mother was willing and available to undergo study procedures such as questionnaires, HIV counselling and testing, CD4 testing, and provide breastmilk at enrolment; iv) the mother was ready to allow her infant to also receive full-course rotavirus vaccination, phlebotomy at enrolment and 1 month post full rotavirus vaccination, and presentation to clinic for collection of stool sample when infant had diarrhoea; and v) intended to remain in their locality and was ready to attend all scheduled visits for the duration of the study [28]. All data was completely de-identified before we accessed it. Although the parent study was granted approval to conduct HIV testing on the mothers, approval for HIV testing in the infants was not obtained due to insufficient sample and therefore HIV status could not be determined.

Sample profile

The original study enrolled 420 mother-infant pairs attending routine infant immunisation clinics between April 2013 and March 2014, and who were followed until mid-2017. Plasma samples were collected from the infants at ages 6, 14 and 52 weeks and stored at -80°C. In the current study, we used the left over plasma samples to test for Shigella specific antibodies in Zambian infants. From a total of 420 leftover serum samples, 259 were insufficient and excluded accordingly. Of the remaining 161, 2 duplicate samples were deleted giving us 159 Fig 1.

Fig 1. Sample flow diagram.

A total of 159 longitudinal plasma samples collected from infants at ages 6, 14 and 52 weeks were tested for IgG antibodies to S. flexneri 2a LPS and 135 were tested for IgG antibodies S. sonnei LPS. IgA antibodies to the same antigens (134 triplets of sera to S. flexneri 2a LPS and 156 to S. sonnei LPS) were also tested. Socio-demographic, clinical and anthropometric data for both infants and their mothers were obtained from the existing database of the rotavirus vaccine study.

Laboratory procedures

Shigella specific enzyme-linked immunosorbent assay

Enzyme-Linked Immunosorbent Assay (ELISA) for S. flexneri 2a and S. sonnei specific LPS IgG and IgA antibodies was conducted at the Tel Aviv University School of Public Health and was performed as previously described [29]. Briefly, 96-well polystyrene microtiter plates (cat. No. 3590; Corning-Costar) were coated with 5μg/ml of S. flexneri 2a LPS or 0.5μg/ml of S. sonnei LPS in 0.05 M carbonate buffer (pH 9.6) for 1 hour at 37°C. After removal of coating solution, unbound sites were blocked through 1-hour incubation at 37°C. The wells were then washed twice with phosphate buffered saline containing 0.05% Tween 20 (PBST). Duplicates of test plasma samples 2-fold serial diluted (8 dilutions) in blocking buffer were added to coated wells and incubated overnight at room temperature. The plates were then washed four times with PBST and alkaline phosphatase conjugated antibody anti-human IgG (cat. No. 5220–0348, KPL antibodies and conjugates; Sera Care, MA, USA) or IgA (cat. No.5220-0347, KPL antibodies and conjugates; Sera Care, MA, USA) diluted at 1:5000 and 1:8000, respectively, were then added and incubated overnight at room temperature. Wells were washed four times with PBST and phosphatase substrate (para-Nitrophenylphosphate-pNPP One component Microwell Substrate Solution, cat. No. 0421–01, Southern Biotech, AL, USA) was added for 15 min at room temperature. Colour development was stopped by the addition of 3M Sodium Hydroxide. Optical density (OD) was measured at 405nm using an ELISA plate reader (Thermo Scientific Multiskan FC; MA, USA). OD values were corrected by subtraction of OD value of blank wells. Results were expressed in end point titres (the last serum dilution yielding an OD of 0.2 or higher).

Statistical analysis

Social demographic characteristics of the participants were summarised using frequencies. We computed geometric mean titres (GMT) and 95% CI for both S. sonnei and S. flexneri 2a IgG and IgA titres at 6 weeks, 14 weeks and 52 weeks. Seroconversion for both S. sonnei and S. flexneri 2a was defined as at least a 4-fold rise in IgG between 6 weeks and 14 weeks and between 14 weeks and 52 weeks. We compared differences in seroconversion by demographic characteristics using Pearson chi-square test and Fisher’s exact test as appropriate. A p-value of 0.05 or less was considered to be statistically significant. All statistical analyses were performed in Stata 16 MP2 (StataCorp, College Station, TX, USA).

Ethical approval

The University of Zambia Biomedical Research Ethics Committee approved the study, while the National Health Research Authority provided the authorisation to conduct the study. A Material Transfer Agreement was also obtained from the National Health Research Authority to ship the plasma samples for testing and analysis at the Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Results

Exploring demographic differences between S. flexneri 2a and S. sonnei

A total of 159 participants were included in this study, among whom 53% were female and 37% were HIV-exposed. Majority of the mothers were above 24 years, and approximately 6% (10/160) of the infants were stunted according to the World Health Organisation (WHO) standards i.e. children are defined as stunted if their height-for-age is more than two standard deviations below the WHO Child Growth Standards median Table 1.

Table 1. Characteristics of the study population.

Characteristics	N (%)
Gender
Female	84 (53.42)
Male	75 (46.58)
HIV exposure
exposed	60 (37.27)
not exposed	101 (62.73)
Diarrhoea Post Vaccination (n = 72)
No	68 (94.44)
Yes	4 (5.56)
Mother’s age
<18	10 (6.21)
18–24	73 (45.34)
24>	78 (48.45)
Wasted
No	91 (56.52)
Yes	70 (43.48)
Stunted (n = 160)
No	150(93.8)
Yes	10(6.3)

Kinetics of specific IgG antibodies to Shigella LPS

At 6 weeks infant age, we found that the IgG GMT against S. sonnei was 311 (95% CI: 259–372; N = 159) whereas for S. flexneri 2a the IgG GMT was 446 (95% CI: 343–580; N = 135) (Fig 2). By 14 weeks lower IgG GMT were observed for both S. sonnei and S. flexneri 2a 104 (95% CI: 88–124) and 183 (95% CI: 147–230), implying a decrease of transplacental maternal IgG and this decreasing trend continued to 52 weeks of age at which IgG antibody titres against S. sonnei and S. flexneri 2a were 41 (95%CI: 34–48) and 163 (95%CI: 130–203) respectively.

Fig 2.

Kinetics of infant Shigella LPS specific IgG antibody titres form 6 to 52 weeks for S. flexneri 2a Panel A. Similarly, kinetics of S. sonnei Panel B. In both panels, transplacentally transferred maternal antibodies to S. flexneri 2a Panel A and S. sonnei Panel B were highest at 6 weeks and decreased by 52 weeks. The decrease is statistically significant between 6 and 14 and not between 14 and 52 weeks for antibodies to S. flexneri 2a LPS. A similar trend was observed for S. sonnei LPS IgG antibodies with the decrease when compared to 6 weeks titres statistically significant at all other time points.

IgA GMT (95% CI) to S. flexneri 2a were <25 at 6 and 14 weeks and 52 (44–62) at 52 weeks. IgA GMT to S. sonnei were also <25 at 6 and week 14 weeks and 36 (31–41) by 52 weeks. In both instances, between 6 and 14 weeks IgA antibody titres were generally low with an observed rise between 14 and 52 weeks, indicative of potential exposure to Shigella in a period when infants are able to develop their own IgA Fig 3.

Fig 3.

Kinetics of infant Shigella LPS specific IgA antibody titres to S. flexneri 2a in Panel A and kinetics of infant Shigella LPS specific IgA antibody titres to S. sonnei in Panel B. In both Panels, infant Shigella LPS specific IgA antibody titres to S. flexneri 2a and to S. sonnei were undetectable in most individuals with a few showing an elevation by 14 weeks and a few more by 52 weeks.

Exploring demographic differences between S. flexneri 2a and S. sonnei

We also investigated differences in demographic characteristics between infants with increased IgG antibody titres between 52 and 14 weeks, for both S. flexneri 2a and S. sonnei and found no significant differences (Table 2).

Table 2. Differences between children with a significant 4-fold rise in titre to S. flexneri 2a LPS and S. sonnei LPS by demographic characteristics.

Characteristics	n(%) tested for S. flexneri at 52 and 14 weeks	S. flexneri 2a IgG rise (52 weeks vs 14 weeks) n = 135	p-value	n(%) tested for S. sonnei at 52 and 14 weeks	S. sonnei IgG rise (52 weeks vs 14 weeks) n = 159	p-value
Gender
Female	72(53.3)	24 (33.3)	0.69	85(53.5)	14 (16.5)	0.19
Male	63(46.7)	23 (36.5)		74(46.5)	7 (9.5)
HIV exposure
Exposed	48(35.6)	18 (33.3)	0.63	60(37.7)	7 (11.7)	0.66
Unexposed	87(64.4)	29 (37.5)		99(62.3)	14 (14.1)
Mothers’ age
<18	6(4.4)	2 (33.3)	0.4	10(6.3)	1 (10)	0.94
18–24	64(47.4)	26 (40.6)		72(45.3)	10 (13.9)
24>	65(48.1)	19 (29.2)		77(48.4)	10 (13)
Stunted 2
No	125(94.7)	44 (35.2)	1 1	147(94.2)	19 (12.9)	0.6 1
Yes	7(5.3)	2 (28.6)		9(5.8)	0 (0)

¹ Fisher’s exact test.

² n = 132 for S. flexneri and 159 for S. sonnei.

IgG anti-S. sonnei and S. flexneri 2a LPS response

We observed a similar trend in the decline over time of S. flexneri 2a and to S. sonnei-specific GMT with recorded higher IgG GMT between 6 to 14 weeks and the lowest at 52 weeks (Table 3). Likewise, the geometric mean fold change in titre (95%CI) between 14 to 52 weeks when compared to 6 to 14 weeks titre was 0.9; 95% CI: 0.7–1.2 for S. flexneri 2a and 0.4; 95% CI: 0.30–0.5 to S. sonnei respectively (Table 3). Whereas at 52 weeks, the geometric mean fold change in titres when compared to the titre at 6 weeks was 0.4; 95% CI: 0.3–0.5 to S. flexneri 2a and 0.1; 95% CI: 0.1–0.2 to S. sonnei (Table 3).

Table 3. Serum IgG anti-S. flexneri 2a or S. sonnei LPS response.

IgG:
Period	# of infants		Geometric mean titre (95%CI) 1		Geometric mean fold change in titre (95%CI)		Seroconversion, n(%); 95%CI
	S. flexneri	S. sonnei	S. flexneri	S. sonnei	S. flexneri	S. sonnei	S. flexneri	S. sonnei
Week 6–14	135	159	446 (343–580)	311 (259–372)	0.4 (0.3–0.5)	0.3 (0.3–0.4)	7 (5.2); (2.1–10.4)	5 (3.1); (1.0–7.1)
Week 14–52	135	159	183 (147–230)	104 (88–124)	0.9 (0.7–1.2)	0.4 (0.30–0.5)	36 (26.7); (19.4–35.0)	12 (7.5); (4.0–12.8)
Week 6–52	135	159	163 (130–203)	41 (34–48)	0.4 (0.3–0.5)	0.1(0.1–0.2)	21 (15.6); (9.9–22.8)	5 (3.1); (1.0–7.2)

We found that 5% infants showed a 4-fold rise in titre to S. flexneri 2a between 6 and 14 weeks, 27% between 14 and 52 weeks and finally 16% between 6–52 weeks (Table 3). Also, 3% infants showed a 4-fold rise in IgG titre to S. sonnei LPS between 6 and 14 weeks and 8% between 14 and 52 weeks respectively (Table 3).

IgA GMT between 6 to 14 weeks were lowest rising at 52 weeks (Table 4). Similarly, there was no observed response in the geometric mean fold change in titre (95%CI) between 6 and 14 weeks with only a minimal rise at 52 to S. flexneri 2a (2.1; 95% CI: 1.8–2.5) and to S. sonnei (1.4; 95% CI: 1.2–1.6) at 52 weeks (Table 4).

Table 4. Serum IgA anti-S. flexneri 2a or S. sonnei LPS response.

IgA:
Period	# of infants		Geometric mean titre (95%CI) 1		Geometric mean fold change in titre (95%CI)		Seroconversion, n(%); 95%CI
	S. flexneri	S. sonnei	S. flexneri	S. sonnei	S. flexneri	S. sonnei	S. flexneri	S. sonnei
Week 6–14	134	156	<25	<25	NR	NR	4* (3.0); (1.2–7.4)	NR
Week 14–52	134	156	<25	<25	NR	NR	37 (27.6); (20.7–35.7)	16 (10.3); (6.4–16.0)
Week 6–52	134	156	52 (44–62)	36 (31–41)	2.1 (1.8–2.5)	1.4 (1.2–1.6)	39 (29.1); (22.1–37.3)	16 (10.3); (6.4–16.0)

¹GMT is reported at week 6, 14 and 52 respectively.

*4 respective titers on week 14 are: 200,100,100,400.

Approximately 3% individuals showed 4-fold rise in IgA titres to S. flexneri 2a between 6 and 14 weeks, 28% between 14 and 52 weeks and finally 29% between 6–52 weeks (Table 4). Also, 10% infants showed a 4-fold rise in IgA titres to S. sonnei LPS between 14 and 52 weeks and between 6 and 52 weeks respectively (Table 4).

IgG and IgA antibody profile among infants

When individual IgG antibody titres were further analysed, we found that S. flexneri 2a IgG GMT kinetics from 6 to 52 weeks infant age generally started out with a high GMT at 6 weeks, decreased at 14 weeks with a gradual increase from 14 weeks through 52 weeks (Fig 4). Also, a similar trend was noted in S. sonnei (Fig 4).

Fig 4. The individual IgG and IgA response profile among infants from 6 to 52 weeks.

In both S. flexneri 2a and S. sonnei, IgA GMTs were very low at 6 weeks and increased markedly from 14 weeks onwards (Fig 4).

Discussion

We carried out a sero-epidemiologic study of S. flexneri 2a and S. sonnei specific antibodies in the first year of life in Zambian infants and here report on maternal antibody transfer, decay and titre kinetics at the three time points for which we had available samples to test. Furthermore, our results are consistent with early exposure to Shigella we have as indicated by the 4-fold rise in IgG and IgA antibodies to S. flexneri 2a and S. sonnei LPS following the decrease in IgG transferred maternal antibodies.

Overall, our results indicate that between 6–14 weeks infant age IgG antibodies to both S. flexneri 2a and S. sonnei are highest and suggestive of transplacental transfer as has been demonstrated in reports from Israel [17] and Brazil [30]. Higher neonatal IgG titres have equally been reported for other pathogens like influenza virus [31], measles virus [32], and Bordetella pertussis as evidence of maternal transfer [33]. Similar work in Malawian children attributed reduced susceptibility to non-typhoidal Salmonella to transplacentally acquired antibodies [34, 35]. We thus infer that infants in our cohort were born from mothers with high levels of Shigella IgG anti-LPS antibodies passively acquiring these antibodies through trans placental transfer. It has been shown that serum IgG antibodies to Shigella LPS correlate with protection and this might explain the lowest incidence rates of shigellosis in the first year of life in both LMICs and high income countries endemic for shigellosis [15, 36].

Despite this assumption of maternal transfer in our cohort, our results must be interpreted with caution as we used left over plasma samples and were unable to test sera from the mothers to demonstrate correlations as shown elsewhere [33]. Further, due to limited clinical data, we could not analyse for factors that might influence efficient transfer of antibodies like maternal antibody concertation [33], pregnancy related complications (e.g. diabetes) [37] and gestation age [30].

We also observed a notable decrease of the transferred antibodies to both S. flexneri 2a and S. sonnei by 14 weeks, suggesting maternal antibody reduction. We thus postulated a gradual increase in infant immune competence. In fact, we began to see rises in IgG and IgA to both S. flexneri 2a and S. sonnei between 14–52 week time point suggesting that infants began to mount their own individual responses possibly in response to newly acquired infection. While we could not associate these observations to confirmed clinical disease, we postulate that this might indeed be the age around which supplementary feeding gets introduced, and infants begin to get exposed to potentially contaminated feeds [38] and to other modes of fecal-oral transmission (person-to-person, fomite and fly-borne).

Our results also showed that there were more infants responding to S. flexneri 2a compared to S. sonnei when data was analysed by group. Previous data show that generally S. flexneri 2a is much more common in LMICs [5] and data from Zambia seem to support this finding as S. flexneri was recently reported to be more common compared to other serotypes [39]. Higher prevalence of flexneri 2a in Zambia supports our observed drop in titres against S. sonnei by 52 weeks when compared to those of S. flexneri 2a. Additionally, the moderate drop in S. flexneri 2a antibodies between 14 and 52 weeks could mean exposure in some infants after maternal antibody deterioration. These findings are further strengthened by the notable percent of infants showing a significant rise in both IgG and IgA titres to both S. flexneri 2a and S. sonnei by 52 weeks. Furthermore, simultaneous fold-increase analysis showed that there were more infants with a four-fold rise in antibody titres at 52 weeks to S. flexneri 2a compared to S. sonnei. Nonetheless, it remains clear that S. sonnei infections are present and future Shigella vaccines should confer protection against these both strains.

It appears that a potential timing of vaccination against shigellosis in infants in Zambia would be after 14 and before 52 weeks of age because: i) the possible interference with maternally acquired antibodies decreases after 14 weeks; ii) infants are still within the age-eligible period for visits for routine immunisations for other vaccines such as those against pneumonia, diphtheria, pertussis etc. and iii) the risk of natural exposure to infection begins to rise as most mothers start to introduce supplementary feeds and as a result of other modes of fecal-oral transmission (person-to-person, fomite and fly-borne).

Indeed other studies investigating maternal antibody longevity have likewise reported a drop in maternal antibodies around the same period [18, 40]. However, while it is postulated that administration of vaccines close to when maternal antibodies decrease would be very attractive, it is not guaranteed as some evidence has shown that residual concentration of maternal placentally transferred antigen-specific antibodies at the time of immunisation potentially inhibit the immune response to infant vaccination against some antigens [41]. It remains an important research question as to whether such residual maternal antibodies will actually interfere with vaccine uptake or functionality of induced vaccine responses in LMIC infants. Another important factor for future decisions on the timing of administration of the first dose of vaccine will be the immunogenicity of the candidate vaccine so early in infancy.

Our study has several strengths as well as limitations. Notable strengths include first, the measurement of IgG and IgA antibodies to Shigella LPS which makes it possible to assess the individual infant exposure to both S. flexneri 2a and S. sonnei at the various points in a longitudinal cohort of infants; to our knowledge, this is the first such longitudinal observation in African infants. While it appears that a potential timing of vaccination would be after 14 and before 52 weeks of age to ensure early infant protection against shigellosis, a more comprehensive sero-epidemiological study together with the month on month incidence of shigellosis will help indicate a narrower and optimal age for vaccination.

Limitations include the inability to assess the associations between infant titres perceived to be acquired by placental transfer and maternal serum titre levels. The study also had insufficient data on clinical disease as the passive diarrhoea surveillance captured only a few cases that self-reported to the facility; this would miss all the subclinical infections or even those managed at home, and yet such infections still contribute to the evolution of immunity against disease in the infant.

Nonetheless, these data do contribute to global knowledge on shigellosis in endemic settings and certainly demonstrate early natural exposure in to Shigella in infants. Here we affirm the need for a preventive vaccine and also propose an optimal window for delivery of the vaccine.

Conclusion

Shigella exposure is common in LMICs and maternal IgG is readily transferred across the placenta, decreasing by 14 weeks of age in the majority of infants. Early natural exposure to Shigella thereafter is associated with significant rises in specific antibodies to S. flexneri 2a and S. sonnei LPS. A vaccine against shigellosis is needed and is desirable to target both S. flexneri 2a and S. sonnei serotypes within a multivalent formulation. A potential timing of vaccination would be after 14 and before 52 weeks of age to ensure early infant protection against shigellosis.

Recommendations

Appropriate monitoring and prevention strategies can be targeted to such vulnerable population with a marginally primed immune system.

Data Availability

Data will be made available as SOI to any interested researchers upon request. The CIDRZ Ethics and Compliance Committee is responsible for approving such request. To request data access, one must write to the Committee Chair/Chief Scientific Officer, Dr. Roma Chilengi, (Roma.Chilengi@cidrz.org) or the Secretary to the Committee/Head of Research Operations, Ms. Hope Mwanyungwi (Hope.Mwanyungwi@cidrz.org). Dataset request must include contact information, a research project title, and a description of the analysis being proposedas well as the format it is expected. The requested data should only be used for the purposes related to the original research or study. The CIDRZ Ethics and Compliance Committee will normally review all data requests within 48 – 72 hours (Monday - Friday), and provide notification if access has been granted or additional project information is needed, before access can be granted.

Funding Statement

This work was supported by the GCRF Networks in Vaccines Research and Development which was co-funded by the MRC and BBSRC. BactiVac grant # BVNC P-04. The original cohort study was funded by the National Institutes for Health (NIH), USA, through an R01 grant 1R01AI099601.